Background. Increased pneumococcal loads are associated with severe outcomes. We determined the prevalence of pneumococcal DNA in blood specimens from patients hospitalized with acute lower respiratory tract infection and identified factors associated with invasive pneumococcal pneumonia, bacterial loads, and death.
In 2004, lower respiratory tract infections were the third most common cause of death globally, accounting for approximately 4.2 million deaths [1] . In South Africa, in 2008, influenza and pneumonia ranked the second most common natural cause of death in all ages, accounting for 8% of deaths [2] . Streptococcus pneumoniae is a common, often predominant cause of bacterial pneumonia [3] [4] [5] .
The etiological diagnosis of community-acquired pneumonia is difficult to elucidate because of inadequate diagnostic tests. As a result, the incidence of pneumococcal pneumonia is underestimated [6] . Realtime polymerase chain reaction (PCR) offers a fast and sensitive alternative to the gold standard, blood culture, and is not dependent on the viability of the organism. The detection of pneumococcal DNA in blood has been shown to be a potentially useful diagnostic tool [7] [8] [9] [10] [11] , and PCR compared favorably with culture and serological tests when used to diagnose pneumococcal infection in children with lower respiratory tract infections [10, 12] . In addition, real-time PCR has been used to quantify bacterial loads in blood, which may serve as useful markers of community-acquired pneumonia [8, 9, 13, 14] .
Human immunodeficiency virus (HIV) infection is a known risk factor for invasive pneumococcal disease [15, 16] . Infection with influenza virus is commonly complicated by secondary pneumococcal infection, resulting in severe disease and increased mortality [17, 18] . Respiratory viral infections are specifically associated with increased rates of invasive pneumococcal disease [19, 20] and are considered a risk factor for pneumococcal pneumonia [21, 22] . Pneumococcal loads in clinical specimens have been shown to be directly related to severity of illness and mortality [9, 13, 23] . However, there are few data on the effect of HIV infection and respiratory virus coinfections on pneumococcal loads. We used quantitative real-time PCR to determine the prevalence of pneumococcal DNA among patients hospitalized with acute lower respiratory tract infection and to identify factors associated with invasive pneumococcal pneumonia, pneumococcal loads, and death.
MATERIALS AND METHODS

Study Design and Setting
In South Africa, a low to middle income country of about 50 million people [24] , influenza virus circulation occurs mainly during winter (May to August) [25] . In 2006, approximately 11% of the South African population (4% of children aged <5 years) was infected with HIV [26] .
We conducted a prospective hospital-based observational study as part of the Severe Acute Respiratory Illness surveillance program that started in February 2009 and aims to describe the etiology of and risk factors for acute lower respiratory tract infection in South Africa. For this study, blood specimen collection for the detection of S. pneumoniae started in May 2009 and continued through April 2011. The study was implemented at 6 public referral hospitals at 4 surveillance sites in 4 provinces of South Africa.
Patients were enrolled if they met the World Health Organization's (WHO's) acute lower respiratory tract infection case definition and had symptom onset within 7 days from admission [27] . A case in children aged 2 days to <3 months included any hospitalized patient with physician-diagnosed sepsis or physician-diagnosed acute lower respiratory tract infection, irrespective of signs and symptoms. A case in children aged 3 months to <5 years included any hospitalized patient with physician-diagnosed acute lower respiratory tract infection, including bronchitis, bronchiolitis, pneumonia, and pleural effusion. A case in individuals aged ≥5 years included any hospitalized patient presenting with manifestation of acute lower respiratory tract infection with recent (≤7 days) onset of fever (>38°C) and cough or sore throat and shortness of breath or difficult breathing with or without clinical or radiographic findings of pneumonia.
A standardized questionnaire was used to collect demographic and clinical information. Vaccination history was verified from the patient's Road to Health card, which was available for review on admission in 69% of children (1860/2691) <5 years of age. Blood cultures were performed at the discretion of the clinician, and results were retrieved from the patient's hospital records.
Sample Collection and Processing
Whole blood samples were collected in ethylenediaminetetraacetic acid-containing vacutainer tubes within 24 hours of hospital admission. Respiratory specimens, including oropharyngeal and nasopharyngeal swabs (Dryswab, Medical Wire and Equipment, Corsham, England) for patients aged ≥5 years or nasopharyngeal aspirates for children aged <5 years, were placed in virus transport medium (Highveld Biological, Johannesburg, South Africa) upon collection. Swabs collected from the same patient were placed in the same virus transport medium. Specimens were stored at 4°C and transported to the National Institute for Communicable Diseases for testing.
Detection and Quantification of S. pneumoniae DNA was extracted from 200 μL of whole blood, using the Roche MagNA Pure LC 2.0 instrument and DNA Isolation kit III for bacteria (Roche, Mannheim, Germany) according to the manufacturer's instructions. Extracted DNA was eluted into 100 μL of elution buffer and stored at −20°C.
A case of invasive pneumococcal pneumonia was defined as the identification of S. pneumoniae in the blood specimen, using a single-target (lytA) quantitative real-time PCR assay adapted from Carvalho et al. [28] . The 25-μL PCR reaction contained 1× TaqMan gene expression mastermix (Applied Biosystems, Foster City, CA); 200 nM each of forward primer, reverse primer, and probe (5′FAM); and 2.5 μL of extracted DNA. The following universal cycling conditions were used: 50°C for 2 minutes, 95°C for 10 minutes, and 40 cycles of 95°C for 15 seconds and 60°C for 1 minute. Samples with a cycle threshold (C t ) value of >40 were recorded as negative. A standard curve was prepared using serially diluted DNA extracts from a known quantity (confirmed spectrophotometrically) of S. pneumoniae ATCC49619 and was used to calculate pneumococcal loads (DNA copies/mL). For blood-culture positive, lytA-negative cases, blood specimens were reextracted and PCR repeated.
Detection of Respiratory Viruses
Respiratory samples were tested by multiplex reverse-transcription real-time PCR as previously described [29] for the following viruses: influenza virus types A and B, adenovirus, enterovirus, rhinovirus, human metapneumovirus, respiratory syncytial virus (RSV), and parainfluenza virus types 1-3. The influenza virus A-positive specimens were subtyped using methods from the WHO Collaborating Center for Influenza, Centers for Disease Control and Prevention.
Determination of HIV Status
HIV results were obtained from a combination of 2 sources: (1) patient clinical records, where available, and (2) for consenting patients, an anonymized linked dried blood spot tested at the NICD. For a large number of patients for whom both results were available, the NICD result was used. Testing included HIV enzyme-linked immunosorbent assay (ELISA) for patients aged ≥18 months and PCR testing for children aged <18 months if the ELISA was reactive. A comparison of HIV prevalence among patients with anonymized linked testing results (2926/ 5636; 52%) and patients with clinical records (1348/2674; 50%) revealed no difference (P = .201).
Statistical Analysis
To identify factors associated with lytA positivity, bacterial load, and death, we included potential determinants for and outcomes or characteristics of the primary end points of the analysis. Univariate comparisons were performed using logistic regression. In addition, we implemented 3 multivariable models to identify factors associated with (1) lytA positivity among cases with available lytA results, (2) pneumococcal load among lytA-positive patients, and (3) mortality among lytA-positive patients. The lytA positivity and mortality models were implemented using stepwise backward selection logistic regression. For the mortality analysis, 4 binary variables were generated for the pneumococcal load (cutoffs, 100, 1000, 10 000, and 100 000 DNA copies/mL) and included in the model as a predictor to investigate the effect of different pneumococcal loads on mortality. For the analysis of factors associated with pneumococcal load, we used a proportional-odds (ordinal) model, which assumes that the ordinal outcome variable represents categories of an underlying continuous variable. The outcome variable ( pneumococal load) was categorized into 5 levels, as follows: <100, 100 to <1000, 1000 to <10 000, 10 000 to <100 000, and ≥100 000 DNA copies/mL. The coefficients of the proportional-odds model (and associated odds ratio [OR]) measure the effect of a predictor on the log odds of being above a specified level, compared with the log odds of being at or below the specified level. In addition, we compared the prevalence (and associated OR) of covariates in each bacterial load level to the lowest bacterial load category (<100 DNA copies/mL).
Covariates with a P value <.2 in the univariate analysis were assessed for significance in the multivariable analysis, and statistical significance was assessed at P < .05. Pairwise interactions were assessed by the inclusion of product terms for all variables remaining in the final multivariable additive models. Pneumococcal cases positive on blood culture only were excluded from the analysis because no bacterial load data were available. The statistical analysis was implemented using Stata, version 11 (StataCorp, College Station, TX).
Ethics Approval
The protocol was approved by the University of the Witwatersrand Human Research Ethics Committee (M081042) and the University of KwaZulu Natal Biomedical Research Ethics Committee (BF157/08).
RESULTS
Demographic and Epidemiologic Characteristics of the Study Population and Factors Associated With lytA Positivity
From May 2009 through April 2011, we enrolled 8523 cases and S. pneumoniae results were obtained from 6396 patients (75%). Of these, 2969 (46%) were males, and 2753 (43%) were children ≤5 years (Table 1) . Patients' age ranged between 2 days and 92 years (median age, 24 years). A total of 5855 of 6396 patients (92%) had a known HIV status, and 2965 (51%) were HIV positive (Table 1) The overall pneumococcal detection rate was 7% (422/6396). The highest detection rate was observed in the 19-44-year age group (9%; 203/2280; Table 1 ). Cases of invasive pneumococcal pneumonia were detected throughout the year (Figure 1) . However, higher numbers of cases were detected concomitantly with the circulation of influenza virus (Figure 1) Figure 1 ). In 2009, following the introduction of influenza A(H1N1)pdm09 in the country, South Africa experienced 2 distinct waves of influenza virus circulation. The first wave was dominated by influenza A(H3N2), followed by influenza A(H1N1)pdm09. In the same year, a biphasic detection of invasive pneumococcal pneumonia was observed concomitantly with the circulation of the 2 influenza virus A subtypes (Figure 1 ).
In the univariate analysis, among other factors ( associated with lytA positivity. Conversely, RSV and rhinovirus were significantly less associated with lytA positivity in the univariate analysis (Table 1) (Table 1) , HIV (adjusted OR [aOR], 1.9; 95% CI, 1.5-2.4) and influenza virus (aOR, 1.6; 95% CI, 1.1-2.2) infections remained significantly associated with lytA positivity. In addition, patients with invasive pneumococcal pneumonia were more likely to present late (>2 days from symptom onset; aOR, 2.0; 95% CI, 1.5-2.7), to have longer (≥5 days) hospitalization time (aOR, 1.3; 95% CI, 1.1-1.6), to receive antibiotic treatment during admission (aOR, 6.1; 95% CI, 1.5-24.9), and to require oxygen therapy (aOR, 1.8; 95% CI, 1.4-2.1) and were at greater risk of death (aOR, 1.5; 95% CI, 1.1-2.2).
Factors Associated With Pneumococcal Load Among lytAPositive Cases
Among the 422 lytA-positive cases, the overall pneumococcal loads ranged from 1.2 to 6.3 log DNA copies/mL, with a median of 3.1 log DNA copies/mL. The median pneumococcal loads by age group were 2.8, 3.0, 3.4, 3.3, and 3.1 log DNA copies/mL among individuals aged <2 years, 2-5 years, 6-18 years, 19-44 years, and ≥45 years, respectively. On multivariable analysis (Table 2) , HIV and influenza virus infections were significantly associated with elevated pneumococcal load. The prevalence of HIV infection increased from 50% (16/32) among patients with a pneumococcal load of <100 DNA copies/mL to 96% (25/26) among patients with a pneumococcal load of ≥100 000 DNA copies/mL (aOR [ proportional-odds model], 2.4; 95% CI, 1.6-3.6). Similarly, the prevalence of influenza virus infection was 6% (2/32) among patients with a pneumococcal load of <100 DNA copies/mL, compared with 31% (8/ 26) among patients with a pneumococcal load of ≥100 000 DNA copies/mL (aOR [ proportional-odds model] 1.4; 95% CI, 1.2-2.1). In addition, individuals with higher pneumococcal loads were more likely to require oxygen therapy during hospitalization and were at greater risk of death.
A subanalysis restricted to cases positive for both pneumococcus and influenza virus revealed no difference in the association of influenza virus subtypes with pneumococcal load; however, the sample size was small. The mean pneumococcal load was 82 732 (n = 14), 34 906 (n = 17), and 64 487 (n = 15) for patients infected with influenza A(H3N2), A(H1N1) pdm09, and influenza B, respectively (P = .127).
Factors Associated With Mortality Among lytA-Positive Patients
The outcome of hospitalization was available for 99% of patients (6374/6396) with lytA results. The case-fatality ratio was higher among lytA-positive patients (43/421; 10%), compared to lytA-negative patients (300/5953 [5%]; P < .001). On univariate analysis, factors associated with increased mortality among the lytA-positive individuals were HIV infection and pneumococcal loads of ≥10 000 or ≥100 000 DNA copies/mL, as well as different markers of disease severity (Table 3) .
On multivariable analysis (Table 3) , lytA-positive patients who had a load of ≥10 000 DNA copies/mL (aOR, 3.6; 95% CI, b Calculated from observations with available data for all covariates statistically significant in the multivariable analysis (n = 390).
c The following covariates were assessed for significance in the multivariable analysis: age, sex, hospital, season of the year, underlying illness, influenza virus infection, infection with respiratory viruses other than influenza virus, HIV infection, alcohol consumption, smoking, duration of symptoms, length of hospitalization, antibiotic use ≤24 hours before admission, antibiotic use during admission, oxygen therapy, admission to the intensive care unit, and outcome.
1.8-7.2) and presented to hospital late (≥5 days from onset of symptoms; aOR, 3.4; 95% CI, 1.6-7.0) were at increased risk of death. In addition, patients who died were more likely to require oxygen therapy during admission (aOR, 4.7; 95% CI, 2.1-10.4) and had a shorter (<5 days) length of hospitalization (OR, 0.3; 95% CI, .2-.7), indicating a fulminant progression of illness.
Association Between lytA and Blood Culture Positivity
In total, 18% of cases (1120/6396) had blood culture results available. Of these, 2% (23/1120) were recorded as culture positive for pneumococcus. From this same set of cases, 10% (116/ 1120) were PCR positive for pneumococcus. Of the 23 culturepositive cases, 9 (39%) were negative by real-time PCR. One of these 9 patients died.
DISCUSSION
In this study, we detected pneumococcal DNA in blood specimens of patients hospitalized with acute lower respiratory tract infection as a marker for pneumococcal pneumonia. HIV infection and influenza virus coinfection were independently associated with invasive pneumococcal pneumonia and elevated blood pneumococcal loads. In addition, bacterial loads in excess of 10 000 DNA copies/mL were associated with an increased risk of death. Real-time PCR detected 4-fold more cases of invasive pneumococcal pneumonia than blood culture alone. The association between high blood bacterial load and severe disease, including mortality, is well described [9, 13, 30] . In this study, HIV infection was found to be associated with an increased risk of invasive pneumococcal pneumonia and elevated pneumococcal load. This is consistent with previous findings [13] in which HIV-infected children with pneumonia had higher pneumococcal loads than HIV-uninfected children.
PCVs have been shown to be safe and effective in reducing pneumococcal disease in HIV-infected children [31] [32] [33] and adults [34] . Currently in South Africa, PCV is advocated for use in children. Based on the results of this study, vaccination of HIV-infected individuals of all ages may reduce the risk of invasive pneumococcal pneumonia and associated mortality in this group. Similarly, in this study influenza virus infection was associated with an increased risk of invasive pneumococcal pneumonia and an elevated pneumococcal load. A number of mechanisms have been proposed for the synergistic interaction between influenza virus and pneumococcus, including increased bacterial colonization as a result of epithelial cell damage by influenza virus, virus-induced conditions that promote bacterial growth, and increased inflammatory responses [35] . Experimentally infected mice demonstrated a significant reduction in survival rates when coinfected with both pathogens, compared with infection with influenza virus or pneumococcus alone [36] . In addition, increased pneumococcal load has been observed in squirrel monkeys coinfected with influenza virus [37] . The increased risk of invasive pneumococcal pneumonia and elevated pneumococcal load in influenza virus-infected patients observed in this study may, in part, explain the lethality of the dual infection [18] . Recent studies of the 1918 influenza epidemic have indicated that the majority of deaths occurred 7-14 days after infection [38] . The exclusion of cases with a duration of symptoms >7 days in this study may therefore have resulted in an underestimation of the number of secondary pneumococcal infections. Studies have reported a similar synergistic interaction in children between pneumococcus and other respiratory viruses, such as RSV [19, 39] , but this was not observed in our study, which included all age groups. On multivariable analysis, the protective effect of RSV and rhinovirus that was observed in the univariate analysis was not significant, most likely because of the strong age association of these respiratory viruses.
The blood pneumococcal detection rate observed in patients aged ≤18 years during the early introduction of PCV7 (5%) was lower than the 10% described in a similar study performed in Italian children ≤16 years of age [10] . Based on vaccineprobe studies, pneumococcal pneumonia was estimated to account for 8% of clinical pneumonia cases and 36% of chest radiograph-positive pneumonia cases in children aged <5 years [33] . Although these estimates are still lower than what the true burden of pneumococcal pneumonia is thought to be, real-time PCR detected 5 times as many cases than were detected by blood culture alone. In this study, blood cultures were performed only on a subset of cases, but results were similar to findings by Resti et al. [10] , in which real-time PCR was 4-fold more sensitive than blood cultures when used to diagnose pneumococcal community-acquired pneumonia. Real-time PCR enables diagnosis and serotyping from culture-negative specimens [7, 10, 11] , which may be of particular use in developing countries. In addition, the ability to quantify pneumococcus enables individuals at risk of severe outcome to be rapidly identified and treated.
PCV7 vaccination was not associated with a reduced risk of pneumococcal disease. Our study design was not appropriate for the assessment of PCV7 protection because lytA-positive results could not be stratified by serotype, owing to the lack of serotyping data. In addition, the number of patients who were eligible to receive PCV7 and were positive for pneumococcus were too few for meaningful analysis. The pneumococcal detection rate differed significantly among the sites on univariate analysis, most likely because of differences in the HIV prevalence and age distribution of the patients presenting to the respective sites. In the multivariable model, accounting for HIV and age, there was no significant difference observed between the sites.
This study has a number of limitations. First, the assay is not likely to detect all cases of pneumococcal pneumonia, because it is dependent on pneumococcus crossing into the bloodstream. In addition, small volumes of blood were tested in the PCR assay, in comparison with blood culture, which may have resulted in false-negative lytA results. As a result, the true disease prevalence and the magnitude of the identified risk factors for invasive pneumococcal pneumonia may have been underestimated. In addition, the detection of lytA in the blood may reflect transient bacteremias. Limited studies targeting the ply gene have shown that pneumococcus can be detected in the blood of healthy individuals [40, 41] . However, studies targeting the lytA gene, as in our study, did not identify pneumococci in the blood of healthy children colonized with pneumococcus [42, 43] . Second, detailed information on clinical characteristics such as oxygen saturation on admission and chest radiograph findings were not available. Third, surveillance programs such as ours tend to underestimate mortality. This may be due to a number of reasons, including the fact that severely ill patients may be less likely to consent to inclusion in the surveillance or that a proportion of patients may die before hospital admission or shortly after admission but before being approached by surveillance staff. Therefore, our estimates of mortality likely represent a minimum estimate. In addition, we had limited data on CD4 + T-cell counts and HIV treatment; therefore, the effect of these covariates could not be evaluated.
In conclusion, this study highlights the usefulness of realtime PCR on blood specimens as a marker of pneumococcal pneumonia. In addition, the determination of pneumococcal loads at the time of diagnosis may have a role as a prognostic marker for invasive pneumococcal pneumonia-associated mortality. HIV and influenza virus infection were associated with an increase in pneumococcal loads, which, in turn, were associated with an increased risk of death. This may be a pathway by which the immune dysregulation caused by HIV and/or influenza virus infection results in severe outcomes among pneumococcal pneumonia patients.
Notes
